<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00402519</url>
  </required_header>
  <id_info>
    <org_study_id>GEC-ESTRO APBI Trial</org_study_id>
    <nct_id>NCT00402519</nct_id>
  </id_info>
  <brief_title>APBI Versus EBRT Therapy After Breast Conserving Surgery for Low-risk Breast Cancer</brief_title>
  <official_title>Interstitial Brachytherapy Alone Versus External Beam Radiation Therapy After Breast Conserving Surgery for Low-risk Invasive Carcinoma and Low-risk Ductal Carcinoma in Situ (DCIS) of the Female Breast</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Erlangen-Nürnberg Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Erlangen-Nürnberg Medical School</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the role of interstitial brachytherapy alone compared to whole breast irradiation
      in a defined low-risk group of invasive breast cancer or ductal carcinoma in situ concerning
      local failure (all ipsilateral local recurrences) to affirm the hypothesis that local control
      rates in each arm are equivalent.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assess the role of interstitial brachytherapy alone compared to whole breast irradiation
      in a defined low-risk group of invasive breast cancer or ductal carcinoma in situ concerning
      local failure (all ipsilateral local recurrences) to affirm the hypothesis that local control
      rates in each arm are equivalent.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2004</start_date>
  <completion_date type="Anticipated">November 2019</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Local control</measure>
    <time_frame>5-years, 10 ten-years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of acute and late side effects</measure>
    <time_frame>5-years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in cosmetic results</measure>
    <time_frame>5-years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant metastases free survival</measure>
    <time_frame>5-years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival rates (Overall Survival, Disease-free Survival)</measure>
    <time_frame>5-years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Contralateral breast cancer rate</measure>
    <time_frame>5-years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality-of-Life</measure>
    <time_frame>5-years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1300</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>APBI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Accelerated Partial Breast Irradiation with multicatheter brachytherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EBRT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard External Beam Whole Breast Irradiation</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Accelerated partial breast irradiation</intervention_name>
    <description>APBI with PDR and HDR brachytherapy</description>
    <arm_group_label>APBI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>External beam whole breast irradiation</intervention_name>
    <description>Standard Whole breast irradiation</description>
    <arm_group_label>EBRT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stage 0, I or II breast cancer.

          -  Invasive ductal, papillary, mucinous, tubular, medullary or lobular carcinoma.

          -  Ductal carcinoma in situ (DCIS) alone.

          -  No lymph invasion (L0) and no hemangiosis (V0).

          -  Lesions of &gt; 3 cm diameter, histopathologically confirmed.

          -  pN0/pNmi (a minimum of 6 nodes in specimen, or a negative sentinel node is
             acceptable); in the case of DCIS alone axillary staging (e.g. sentinel lymph node
             biopsy) is optional.

          -  M0.

          -  Clear resection margins at least 2 mm in any direction; by lobular histology or DCIS
             histology only the resection margins must be clear at least 5 mm.

          -  For DCIS only: lesions must be classified as low or intermediate risk group (Van Nuys
             Prognostic Index &lt;8).

          -  Unifocal and unicentric DCIS or breast cancer.

          -  Age &gt;= 40 years.

          -  Time interval from final definitive breast surgical procedure to the start of external
             beam therapy or to brachytherapy is less than 12 weeks (84 days). If patients receive
             chemotherapy the radiotherapy can be started before systemic treatment (within 12
             weeks). The radiation therapy can be also given in the interval between the
             chemotherapy courses. It is also possible to start radiation therapy after
             chemotherapy is completed according local protocols as soon as possible within 4 weeks
             after chemotherapy.

          -  Signed study-specific consent form prior to randomization.

        Exclusion Criteria:

          -  Stage III or IV breast cancer.

          -  Surgical margins that cannot be microscopically assessed.

          -  Extensive intraductal component (EIC).

          -  Paget's disease or pathological skin involvement.

          -  Synchronous or previous breast cancer.

          -  Prior malignancy (&lt; 5 years prior to enrollment in study) except non-melanoma skin
             cancer or cervical carcinoma FIGO 0 and I if patient is continuously disease-free.

          -  Pregnant or lactating women.

          -  Collagen vascular disease.

          -  The presence of congenital diseases with increased radiation sensitivity, for example
             Ataxia telangiectatica or similar.

          -  Psychiatric disorders.

          -  Patient with breast deemed technically unsatisfactory for brachytherapy.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vratislav Strnad, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital Erlangen, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Csaba Polgár, MD</last_name>
    <role>Study Chair</role>
    <affiliation>National Institute of Oncology Budapest, Hungary</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Oliver J Ott, MD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital Erlangen, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital AKH Wien, Department of Radiotherapy and Radiobiology</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Erlangen, Department of Radiation Oncology</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Kiel, Department of Radiation Oncology</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Leipzig, Department of Radiation Oncology</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Lübeck, Department of Radiation Oncology</name>
      <address>
        <city>Lübeck</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Barmherzige Brüder, Department of Radiation Oncology</name>
      <address>
        <city>Regensburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Rostock, Department of Radiation Oncology</name>
      <address>
        <city>Rostock</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Institute of Oncology, Department of Radiation Oncology</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kierownik Zakladu Brachyterapii, Cetrum Onkologii</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catalan Institut of Oncology, Department of Radiation Oncology</name>
      <address>
        <city>Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valencian Institut of Oncology, Department of Radiation Oncology</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.apbi.uni-erlangen.de</url>
    <description>Trial Homepage with a short version of the protocol</description>
  </link>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 21, 2006</study_first_submitted>
  <study_first_submitted_qc>November 21, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2006</study_first_posted>
  <last_update_submitted>May 12, 2016</last_update_submitted>
  <last_update_submitted_qc>May 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>accelerated partial breast irradiation</keyword>
  <keyword>multicatheter brachytherapy</keyword>
  <keyword>high dose rate brachytherapy</keyword>
  <keyword>pulsed dose rate brachytherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

